News &amp; Updates

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

MELD best predictor of outcomes in alcohol-related liver disease: study

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

Anticoagulants up risk of bleeding after esophageal dilation procedure

Patients taking anticoagulant medications at the time of esophageal dilation are at increased risk of experiencing gastrointestinal bleeding after the procedure, suggests a study.

Anticoagulants up risk of bleeding after esophageal dilation procedure

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

A recent study suggests that time-restricted eating (TRE) may help reduce weight and improve cardiometabolic health by regulating gut microbiota and serum metabolites.

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

In patients with stable inflammatory bowel disease (IBD) receiving advanced therapies who have comorbid obesity and/or diabetes, adjunctive treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide or tirzepatide does not appear to improve clinical outcomes, according to new research.

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

Multi-pronged strategy may boost CRC screening uptake in SG

30 Jun 2026 by

A multi-pronged approach can help improve colorectal cancer (CRC) screening uptake in Singapore, suggests a recent study.

Multi-pronged strategy may boost CRC screening uptake in SG

30 Jun 2026

Dietary inflammatory index not linked to objective disease activity in IBD

29 Jun 2026 by

Significant associations do not exist between inflammatory potential of the diet and objective markers of disease activity in a cohort of patients with inflammatory bowel disease (IBD), according to a study.

Dietary inflammatory index not linked to objective disease activity in IBD

29 Jun 2026

Glucocorticoid treatment carries risk of adverse psychiatric outcomes

Treatment with oral glucocorticoids may contribute to elevated risks of adverse psychiatric outcomes, including the onset and relapse of common psychiatric disorders, as shown in a population-based cohort study.

Glucocorticoid treatment carries risk of adverse psychiatric outcomes

Paradoxical change in microbiome structure tied to gastric cancer, atrophy

A recent study has found a paradoxical change in the microbiome structure in the development of severe gastric mucosal atrophy, which appears to have a significant association with the progression of gastric atrophy and gastric cancer risk.

Paradoxical change in microbiome structure tied to gastric cancer, atrophy